CTMC / A joint venture between Resilience + MD Anderson Cancer Center

CTMC's 2-Year Birthday Party...   CTMC+ recently celebrated our 2nd anniversary since spinning off from MD Anderson Cancer Center. It's been a busy and productive two years: *cleared six INDs in 18 months with no delays *manufactured (and tested) over 160 GMP batches across 9 clinical programs *renovated and validated four new cleanrooms to bring our total up to 14 *implemented five IT systems to improve productivity, safety, and collaboration with plan to be 100% digital by end of Year 3 *and, so much more. We have a dedicated and talented team of industry and academic experts working collaboratively with our partners to bring life-saving cell therapies to patients faster than ever. Year 3 is going to be even better! #biotech #celltherapy #innovation #venturecapital #TILtherapy #celltherapymanufacturing #endcancer

SAPA-GP (Sino-American Pharmaceutical Professionals Association -Greater Philadelphia)'s 2024 @Philly Cell and Gene Therapy Annual Conference was well-attended by over 500 guests. Jason Bock was honored to give the keynote address: "Accelerating the Cell Therapy Transformation". The cell therapy field could develop through silos...or, accelerate development through intentional, integrated partnerships. CTMC champions collaboration and partnerships so we can bring life-saving cell therapies to patients faster.

Ori Biotech introduced IRO to a packed audience at ISCT, International Society for Cell & Gene Therapy yesterday. In his presentation, "What Got Us Here, Won't Get Us There," Jason Bock reflected on how challenges with variable starting material, variable processes, and variable analytics will continue to hold the cell therapy field back. Automation is one key step that will help accelerate the process to improve access. CTMC is thrilled to have collaborated on this project with the terrific team at Ori and to share such positive data from our comparability studies. #ISCT24 #biotech #celltherapy #celltherapymanufacturing #endcancer Jason C. Foster

Big day at ISCT, International Society for Cell & Gene Therapy 2024 in beautiful Vancouver. The big reveal by Ori Biotech is today at 12PM in Plenary Hall. Come by to learn about the next-generation manufacturing platform with presentations from our CEO, Jason Bock, and Jason C. Foster, Ori's CEO. Be prepared to be WOWED! Chantale Bernatchez Rebecca Lim #biotech #celltherapy #TILtherapy #celltherapymanufacturing #endcancer

Jason Bock had the opportunity to join Harsh Thakkar as a guest on his Life Sciences 360 podcast to talk about: -how CTMC is impacting the development and manufacturing of cell therapies through the close proximity and clinical expertise of our partner, MD Anderson Cancer Center. -the growth of Houston as a biotech hub. -our internal regulatory experience and ability to access MD Anderson's vast knowledge and relationship with the FDA. -the ability of our partners to reduce capital investments on lab and cleanroom space and equipment through use of our 60,000 SF facility in the Texas Medical Center and for our team to tackle the complex logistics of these therapeutics. -the magic word: COLLABORATION!!! Thank you, Harsh, for featuring CTMC on this latest episode. #lifesciences #biotech #celltherapy #investors #endcancer Apple- https://apple.co/3RXPoS1 Spotify- https://spoti.fi/3EbDZbr Amazon- https://amzn.to/3K5gpRv

This isn't your typical drug sponsor + CDMO story. CTMC's Jason Bock says you shouldn't even classify his company as a CDMO. He's not wrong. On #BusinessOfBiotech, Thomas Leitch of KSQ Therapeutics, Inc. and Jason share their partnership story. "Our platform led us to some unique and very promising targets. But as as you alluded to earlier, Matt, having a target is not the same thing as having a therapy. And having a therapy is not the same thing as delivering a patient outcome. And our partnership with CTMC has really helped us accelerate those leads for targeted therapy to uninterrupted supply and and ultimately patient outcomes." Tom Leitch, CTO at KSQ Therapeutics. "And so, because we were running these studies already with MD Anderson - we've done many of these studies - we've got all of those logistics worked out. And so for our partners, they don't have to bother with any of it, we coordinate directly within the MD Anderson clinic. When they have a patient, we work out that we make sure we have a slot and we manufacture that product and then keep them informed and get that product back to the clinicians to infuse into the patients. And so, partners have full visibility into what's going on." Jason Bock, CEO, CTMC+. Thank you, Matthew Pillar and Bioprocess Online, for sitting down with Jason and Tom to hear the story of this exciting partnership. #biotech #celltherapy #TILtherapy #endcancer

90% of all cancers are solid tumors so it is incredible that we finally have an FDA-approved weapon to target some of the most aggressive and deadly cancers starting with melanoma, with more novel cell therapies in the pipeline. Jason Bock connected with Theral Timpson to explain how TILs work and why they are so effective. Thank you, Mendelspod, for featuring CTMC on your podcast. #biotech #celltherapy #TILtherapy #collaboration #endcancer https://lnkd.in/gHABu7XH

Thank you, Fraiser Kansteiner, for bringing Jason Bock and Jason C. Foster together for a dynamic conversation about collaboration in cell therapy.

It was a terrific opportunity for Jason Bock to sit on a panel at the American Society of Gene & Cell Therapy 2024 annual conference with Maher Masoud from MaxCyte, Inc., along with Thomas Leitch and Benjamin Askin from KSQ Therapeutics, Inc., to share the steps we have taken to overcome the many challenges of scaling up cell therapy manufacturing. We continue to collaborate to create solutions to speed up production and reduce the costs of manufacturing the most demanding product ever made for battling cancer. #ASCGT2024 #biotech #celltherapy #TILtherapy #pathtocommercialization #endcancer